HCPCS code J9024: Atezolizumab injection, per 5 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9024 covers

This HCPCS Level II code identifies the subcutaneous combination of atezolizumab and hyaluronidase-tqjs used in cancer treatment. Oncology practices report it for the drug administered by subcutaneous injection; the code's unit count follows the atezolizumab dose, not the amount of hyaluronidase. It represents the combination product, rather than atezolizumab alone in an intravenous formulation.

CMS assigns physician fee schedule status E, so the drug is excluded from the physician fee schedule. When Medicare covers it, CMS classifies it as a Part B drug generally paid through the quarterly ASP drug pricing files, while coverage is left to the Medicare contractor's judgment. Report one unit for each 5 mg of atezolizumab administered. The drug line identifies the medication; CPT 96401 may report subcutaneous antineoplastic administration when separately reportable.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9024 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9024 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9024 rate is calculated

Each of J9024’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9024

J9024 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9024 compared with similar codes

How to choose

J9022Atezolizumab injectionPer 10 mg

Use J9024 for the subcutaneous atezolizumab-hyaluronidase combination; J9022 identifies the conventional intravenous atezolizumab formulation.

96401Chemotherapy injectionSubcutaneous or intramuscular, nonhormonal

This CPT code reports subcutaneous or intramuscular antineoplastic administration, not the drug itself. J9024 reports the atezolizumab-hyaluronidase drug units.

96413Chemo IV infusionInitial drug, first hour

CPT 96413 reports an intravenous chemotherapy infusion service; it does not describe the subcutaneous drug represented by J9024.

Codes related to J9024

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates